GlassScriptPhysician profile
Peter Urazov
NPI 1003070558
$3,729.41
in general payments reported to CMS, 2019-2025
22 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $578 · 2021: $772 · 2022: $1,314 · 2023: $120 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $726.55 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $663.89 | 2019-2023 | Farxiga |
| Daiichi Sankyo INC. | $441.64 | 2019-2022 | |
| Axsome Therapeutics, INC. | $249.78 | 2025 | Auvelity, Sunosi |
| Merck Sharp & Dohme LLC | $220.97 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $194.92 | 2021-2022 | |
| Amarin Pharma, INC. | $183.39 | 2019-2020 | |
| Abbott Laboratories | $181.02 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $132.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.18 | 2020 | |
| Janssen Pharmaceuticals, INC | $123.12 | 2021 | |
| Indivior INC. | $93.19 | 2021-2022 | |
| Pfizer INC. | $78.51 | 2021-2022 | |
| Lilly USA, LLC | $65.68 | 2022 | |
| Dynavax Technologies Corporation | $61.07 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $41.39 | 2020 | |
| Mdd US Operations, LLC | $38.65 | 2019 | |
| Braemar Manufacturing, LLC | $36.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.70 | 2019 | |
| Melinta Therapeutics, LLC | $18.63 | 2019 | |
| Allergan, INC. | $15.48 | 2019 | |
| Gilead Sciences, INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Urazov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.